Scarica l'app Stockscreener
25.50
0.86%
-0.22
Dopo l'orario di chiusura:
25.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$25.72
Aprire:
$25.66
Volume 24 ore:
1.67M
Relative Volume:
0.92
Capitalizzazione di mercato:
$4.30B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
141.67
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
-2.78%
1M Prestazione:
+6.07%
6M Prestazione:
+39.65%
1 anno Prestazione:
+52.79%
Intervallo 1D:
$25.21
$25.68
Intervallo di 1 settimana:
$25.21
$26.50
Portata 52W:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
25.50 | 4.33B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Can swing trading help recover from ACADIA Pharmaceuticals Inc. losses2025 Year in Review & Fast Entry and Exit Trade Plans - Newser
Glioblastoma Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics - The Globe and Mail
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer - CDO Magazine
Market reaction to ACADIA Pharmaceuticals Inc.’s recent newsQuarterly Portfolio Report & Weekly Setup with ROI Potential - Newser
Key metrics from ACADIA Pharmaceuticals Inc.’s quarterly dataWeekly Stock Recap & Accurate Buy Signal Alerts - Newser
Is ACADIA Pharmaceuticals Inc. trending in predictive chart modelsJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
Pattern recognition hints at ACADIA Pharmaceuticals Inc. upsideQuarterly Profit Summary & Long Hold Capital Preservation Tips - Newser
Sector ETF performance correlation with ACADIA Pharmaceuticals Inc.Earnings Summary Report & Free Real-Time Volume Trigger Notifications - Newser
What is ACADIA Pharmaceuticals Inc.’s valuation compared to sector2025 Geopolitical Influence & Weekly High Return Stock Opportunities - khodrobank.com
Is ACADIA Pharmaceuticals Inc. vulnerable to short sellersTrade Analysis Summary & Growth Focused Stock Pick Reports - khodrobank.com
Price action breakdown for ACADIA Pharmaceuticals Inc.2025 Biggest Moves & AI Powered Market Entry Strategies - Newser
Using data models to predict ACADIA Pharmaceuticals Inc. stock movementStock Surge & Risk Managed Investment Strategies - Newser
How to manage a losing position in ACADIA Pharmaceuticals Inc.2025 Market WrapUp & Stepwise Trade Signal Guides - Newser
Is ACADIA Pharmaceuticals Inc. in a consolidation phase2025 Market Outlook & Community Shared Stock Ideas - khodrobank.com
Analyzing drawdowns of ACADIA Pharmaceuticals Inc. with statistical tools2025 Retail Activity & Stepwise Trade Execution Plans - Newser
Can ACADIA Pharmaceuticals Inc. sustain its profitabilityJuly 2025 Review & Low Drawdown Investment Strategies - khodrobank.com
ACADIA Pharmaceuticals Inc. stock daily chart insights2025 Historical Comparison & Reliable Trade Execution Plans - Newser
Signal strength of ACADIA Pharmaceuticals Inc. stock in tech scannersRate Cut & Fast Entry Momentum Alerts - Newser
Does ACADIA Pharmaceuticals Inc. show high probability of rebound2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser
What makes ACADIA Pharmaceuticals Inc. stock price move sharplyJuly 2025 Market Mood & Long-Term Safe Investment Ideas - Newser
ACADIA Pharmaceuticals Inc. stock volume spike explainedTreasury Yields & Proven Capital Preservation Tips - Newser
Can machine learning forecast ACADIA Pharmaceuticals Inc. recoveryWeekly Market Report & Low Drawdown Momentum Ideas - Newser
How to integrate ACADIA Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Gainers & Consistent Growth Equity Picks - Newser
Institutional scanner results for ACADIA Pharmaceuticals Inc.July 2025 Analyst Calls & Low Risk High Reward Ideas - Newser
Published on: 2025-08-30 06:46:07 - Newser
Using portfolio simulators with ACADIA Pharmaceuticals Inc. includedWeekly Trade Recap & Scalable Portfolio Growth Methods - Newser
Published on: 2025-08-29 17:29:10 - Newser
ACADIA Pharmaceuticals Inc. stock chart pattern explained2025 Earnings Surprises & Reliable Entry Point Trade Alerts - Newser
Chart based exit strategy for ACADIA Pharmaceuticals Inc.Portfolio Gains Summary & Expert Approved Momentum Ideas - Newser
Risk adjusted return profile for ACADIA Pharmaceuticals Inc. analyzedJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acadia Pharmaceuticals Inc Azioni (ACAD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 18 '25 |
Sale |
25.18 |
22,000 |
554,024 |
40,130 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):